A Multi-center, Single-arm, Open Label Study to Assess the Efficacy and Safety of Anti-PD-1 Antibody (Penpulimab) Plus Lenalidomide, Rituximab, Gemcitabine and Oxaliplatin (R2-GemOx) in Patients With Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 13 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gemcitabine (Primary) ; Lenalidomide (Primary) ; Oxaliplatin (Primary) ; Penpulimab (Primary) ; Rituximab (Primary)
Indications Diffuse large B cell lymphoma
Focus Therapeutic Use
Acronyms PEARL

Most Recent Events

17 Jun 2022 Trial design presented at the 27th Congress of the European Haematology Association.
03 Mar 2022 Planned End Date changed from 15 Dec 2025 to 15 Feb 2026.
03 Mar 2022 Planned primary completion date changed from 15 Nov 2023 to 15 Jan 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight